SCHEMBL2257798

SCHEMBL2257798

O=C(O)c1ccc(-c2ccc(F)cc2)cc1/C=C/c1cccc2ccc(O)cc12

nearest known ligand 0.60

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ BCL2L1 Q07817 1/20 0.60
▸ BAD Q92934 1/20 0.60
▸ PTPN1 P18031 5/20 0.42
▸ ESR1 P03372 2/20 0.41
▸ ESR2 Q92731 2/20 0.41
▸ DHODH Q02127 4/20 0.40
▸ RELA Q04206 1/20 0.40
▸ MEN1 O00255 2/20 0.40
▸ KMT2A Q03164 2/20 0.40
▸ CYP1B1 Q16678 1/20 0.39
▸ TRPV1 Q8NER1 1/20 0.37
▸ KDM4E B2RXH2 1/20 0.37
▸ MAPT P10636 1/20 0.37
▸ RAB9A P51151 1/20 0.37
▸ GFER P55789 1/20 0.37
▸ LDHA P00338 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2257799 1.00 BCL2L1 (0.60) BCL2L1BADPTPN1ESR1ESR2
SCHEMBL2252475 0.85 BCL2L1 (0.51) BCL2L1BADPTPN1ESR1ESR2
SCHEMBL2252467 0.85 BCL2L1 (0.51) BCL2L1BADPTPN1ESR1ESR2
SCHEMBL2253025 0.84 BCL2L1 (0.56) BCL2L1BADDHODHRELAMEN1
SCHEMBL2253023 0.84 BCL2L1 (0.56) BCL2L1BADDHODHRELAMEN1
SCHEMBL2254705 0.83 BCL2L1 (0.49) BCL2L1BADPTPN1ESR1ESR2
SCHEMBL2254708 0.83 BCL2L1 (0.49) BCL2L1BADPTPN1ESR1ESR2
SCHEMBL2257653 0.82 BCL2L1 (0.64) BCL2L1BADDHODHRELAMEN1
SCHEMBL2257657 0.82 BCL2L1 (0.64) BCL2L1BADDHODHRELAMEN1
SCHEMBL2255098 0.82 BCL2L1 (0.67) BCL2L1BADPTPN1DHODHRELA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1904047-B1 APOPTOSIS PROMOTERS ABBOTT LAB (US) 2013-01-02 — — EP disclosed
US-7989656-B2 Biaryl carboxylic acid apoptosis promoters ABBOTT LABORATORIES (US) 2011-08-02 — — US disclosed
US-20100234456-A1 APOPTOSIS PROMOTERS ABBOTT LABORATORIES (US) 2010-09-16 — — US disclosed
US-7750004-B2 Apoptosis promoters ABBOTT LABORATORIES (US) 2010-07-06 — — US disclosed
EP-1904047-A2 APOPTOSIS PROMOTERS ABBOTT LABORATORIES (US) 2008-04-02 — — EP disclosed
US-20070135392-A1 Apoptosis promoters ABBVIE INC. 2007-06-14 — — US disclosed
WO-2007008627-A2 APOPTOSIS PROMOTERS ABBOTT LABORATORIES (US) 2007-01-18 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100234456-A1 APOPTOSIS PROMOTERS MCL1, BAX, BCL2 BCL2L1 5/4885BAD 11/4885PTPN1 3895/4885
US-20070135392-A1 Apoptosis promoters MCL1, BAX, BCL2 BCL2L1 5/4885BAD 11/4885PTPN1 3895/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback